Pure Global

Clinical Trial - Trial ChiCTR2200057534

Access comprehensive clinical trial information for ChiCTR2200057534 through Pure Global AI's free database. This Not Applicable trial is sponsored by chinese peoples liberation army general hospital and is currently Not yet recruiting. The study focuses on Non-small cell lung cancer.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
ChiCTR2200057534
Not Applicable
Not yet recruiting
Trial Details
Chinese Clinical Trial Registry • ChiCTR2200057534
View on Chinese Clinical Trial Registry
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Untitled Trial
A prospective, multi-center, phase II study of camrelizumab in combination with apatinib and fluzoparib in second-line chemotherapy and immunotherapy for advanced NSCLC that has progressed

Study Focus

Sponsor & Location

chinese peoples liberation army general hospital

This trial drug is sponsored by Jiangsu Hengrui Pharmaceutical Co., Ltd.

China

Timeline & Enrollment

Not Applicable

N/A

Apr 30, 2025

ICD-10 Classifications

Secondary malignant neoplasm of lung
Malignant neoplasm: Lower lobe, bronchus or lung
Malignant neoplasm: Middle lobe, bronchus or lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm of bronchus and lung

Data Source

Chinese Clinical Trial Registry

ChiCTR2200057534

Non-Device Trial